Dr. Wang is a professor of pharmacology and university scholar at the University of Illinois, Chicago. He is associated with various departments and centres of the university such as Department of Biopharmaceutical Sciences, Center for Biomolecular Sciences, Program for Collaborative Research in the Pharmaceutical Sciences, Cancer Center and Sickle Cell Center. A major objective of his laboratory is to understand the mechanisms leading to chronic pain, opioid tolerance and addiction, and opioid-induced hyperalgesia. He is also interested in developing new therapeutic targets as well as novel drugs that can be used for the treatment of pain, where the focus of pain conditions are the pain in sickle cell disease, and chemotherapy-induced pain. Recently professor Zaijie Wang received a MIRA (R35) grant for $4.6M over seven years for a project, entitled “Molecular mechanism and targeting of chronic pain in sickle cell disease”.

Representative Publications:

PKCδ-targeted intervention relieves chronic pain in a murine sickle cell disease model.

CaMKIIα underlies the spontaneous and evoked pain behaviors in Berkeley sickle cell transgenic mice.

IL1A rs1800587 associates with chronic noncrisis pain in sickle cell disease.

Dopamine D3 receptor Ser9Gly and catechol-o-methyltransferase Val158Met polymorphisms and acute pain in sickle cell disease.

Opioid doses and acute care utilization outcomes for adults with sickle cell disease: ED versus acute care unit.

Mechanism-Driven Phase I Translational Study of Trifluoperazine in Adults with Sickle Cell Disease.

Share

Discuss in Social Wall

Twitter

Share to SCDteam

+myBinder